sofosbuvir has been researched along with thiazoles in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boccaccio, V; Bruno, S | 1 |
| Dieterich, DT; Martel-Laferrière, V | 1 |
| Asselah, T; Marcellin, P | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Benhamou, Y; Shiffman, ML | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Shiffman, ML | 1 |
| Agarwal, K; Austin, A; Barclay, ST; Brown, A; Dillon, JF; Dundas, P; Dusheiko, GM; Foster, GR; Fox, R; Hayes, PC; Leen, C; Miller, MH; Millson, C; Ryder, SD; Tait, J; Ustianowski, A | 1 |
| Abd Elghafar, MS; Abd-Elsalam, S; Abdelghaffar, H; Abdelghaffar, K; Al Shafie, A; Badr, M; El-Kassas, M; Esmael, HE; Ezz Eldin, AM; Ezzat, S; Hassany, SM; Kamal, DT; Karam-Allah, H; Medhat, MA; Moaz, I; Moustafa, E; Ossimi, A; Salama, M; Sayed, H; Shamseldeen, A | 1 |
| Akpomiemie, G; Bosch, B; Casas, CP; Ellis, L; Hill, A; Johnstone, H; Owen, A; Simmons, B; Sokhela, S; Venter, WDF; Woods, J | 1 |
6 review(s) available for sofosbuvir and thiazoles
| Article | Year |
|---|---|
Management of HCV patients with cirrhosis with direct acting antivirals.
Topics: Algorithms; Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Liver Cirrhosis; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Time Factors; Uridine Monophosphate | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
HCV F1/F2 patients: treat now or continue to wait.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Treatment Outcome; Uridine Monophosphate | 2014 |
Hepatitis C virus therapy in the direct acting antiviral era.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Sofosbuvir; Thiazoles; Uridine Monophosphate | 2014 |
2 trial(s) available for sofosbuvir and thiazoles
| Article | Year |
|---|---|
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Repositioning; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Humans; Nitro Compounds; SARS-CoV-2; Sofosbuvir; Thiazoles; Treatment Outcome; Viral Load | 2022 |
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.
Topics: Antiviral Agents; Carbamates; COVID-19; Humans; Imidazoles; Nitro Compounds; Pyrrolidines; SARS-CoV-2; Sofosbuvir; South Africa; Thiazoles; Treatment Outcome; Valine | 2022 |
2 other study(ies) available for sofosbuvir and thiazoles
| Article | Year |
|---|---|
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
Topics: Aminoisobutyric Acids; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Interferons; Leucine; Oligopeptides; Proline; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate | 2014 |